ArticleFrontiers in medicine2017
Development of a Multivariate Prediction Model for Early-Onset Bronchiolitis Obliterans Syndrome and Restrictive Allograft Syndrome in Lung Transplantation.
Article in Frontiers in medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 63 citations in OpenAlex.
- Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients.Journal of inflammation research · 2020Trial
- Knowledge structure and academic influence in lung transplantation: a systematically bibliometric analysis of highly cited documents and multi-perspective extensive review.Journal of thoracic disease · 2026Article
- Increased delay to lung transplantation for women candidates: gender-based disparity matters in the lung transplant trajectory.ERJ open research · 2025Article
- Description and first insights on a large genomic biobank of lung transplantation.European journal of human genetics : EJHG · 2025Article
- Prognosis and Risks for Probable Chronic Lung Allograft Dysfunction: A Prospective Multicenter Study.American journal of respiratory and critical care medicine · 2025Article
- Pseudomonas aeruginosa infection correlates with high MFI donor-specific antibody development following lung transplantation with consequential graft loss and shortened CLAD-free survival.Respiratory research · 2024Article
- Blood MMP-9 measured at 2 years after lung transplantation as a prognostic biomarker of chronic lung allograft dysfunction.Respiratory research · 2024Article
- Systems prediction of chronic lung allograft dysfunction: Results and perspectives from the Cohort of Lung Transplantation and Systems prediction of Chronic Lung Allograft Dysfunction cohorts.Frontiers in medicine · 2023Review
- Is there life on the airway tree? A pilot study of bronchial cell vitality and tissue morphology in the ex vivo lung perfusion (EVLP) era of lung transplantation.Artificial organs · 2022Article
- Circulating anti-human leukocyte antigen IgM antibodies as a potential early predictor of allograft rejection and a negative clinical outcome after lung transplantation.Surgery today · 2022Article
- PD-1 expression in transbronchial biopsies of lung transplant recipients is a possible early predictor of rejection.Frontiers in immunology · 2022Observational
- Characterization of chronic lung allograft dysfunction phenotypes using spectral and intrabreath oscillometry.Frontiers in physiology · 2022Article
- Novel approaches for long-term lung transplant survival.Frontiers in immunology · 2022Review
- The potential of ex vivo lung perfusion on improving organ quality and ameliorating ischemia reperfusion injury.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Review
- Management of chronic rejection after lung transplantation.Journal of thoracic disease · 2021Review
- COMP: A Potential Early Biomarker of RAS After Lung Transplantation.Transplantation direct · 2021Article
- A prevalent and culturable microbiota links ecological balance to clinical stability of the human lung after transplantation.Nature communications · 2021Observational
- Chronic Lung Allograft Dysfunction: Review of CT and Pathologic Findings.Radiology. Cardiothoracic imaging · 2021Review
- Chronic lung allograft dysfunction post-lung transplantation: The era of bronchiolitis obliterans syndrome and restrictive allograft syndrome.World journal of transplantation · 2020Review
- Autoantibodies in lung transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 14 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic lung allograft dysfunction and its main phenotypes, bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS), are major causes of mortality after lung transplantation (LT). RAS and early-onset BOS, developing within 3 years after LT, are associated with particularly inferior clinical outcomes. Prediction models for early-onset BOS and RAS have not been previously described.
methodsLT recipients of the French and Swiss transplant cohorts were eligible for inclusion in the SysCLAD cohort if they were alive with at least 2 years of follow-up but less than 3 years, or if they died or were retransplanted at any time less than 3 years. These patients were assessed for early-onset BOS, RAS, or stable allograft function by an adjudication committee. Baseline characteristics, data on surgery, immunosuppression, and year-1 follow-up were collected. Prediction models for BOS and RAS were developed using multivariate logistic regression and multivariate multinomial analysis.
resultsAmong patients fulfilling the eligibility criteria, we identified 149 stable, 51 BOS, and 30 RAS subjects. The best prediction model for early-onset BOS and RAS included the underlying diagnosis, induction treatment, immunosuppression, and year-1 class II donor-specific antibodies (DSAs). Within this model, class II DSAs were associated with BOS and RAS, whereas pre-LT diagnoses of interstitial lung disease and chronic obstructive pulmonary disease were associated with RAS.
conclusionAlthough these findings need further validation, results indicate that specific baseline and year-1 parameters may serve as predictors of BOS or RAS by 3 years post-LT. Their identification may allow intervention or guide risk stratification, aiming for an individualized patient management approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.